Catabasis Pharmaceuticals – pharmaceutical daily

October 5, 2019 Off

Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals will present differentiating safety and tolerability profile of Edasalonexent through more than 55 patient years of exposure, from a phase 2 trial, which showed edasalonexent slowed duchenne muscluar dystrophy progression.

September 30, 2019 Off

Catabasis Pharmaceuticals’ third phase trial of edasalonexent in Duchenne muscular dystrophy exceeds target enrollment

By BusinessWire

Catabasis Pharmaceuticals has enrolled more than expected patients for its third phase PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD), for which it expects the top-line results in the fourth quarter of 2020.

September 27, 2019 Off

Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label…